Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.

Shih-Shih Chen,Jacqueline C Barrientos,Gerardo Ferrer, Morgan King-Richards,Yu-Ju Chen,Priyadarshini Ravichandran,Michael Ibrahim,Yasmine Kieso, Sheila Waters,Jeffery L Kutok, Marisa Peluso,Sujata Sharma,David T Weaver,Jonathan A Pachter,Kanti R Rai,Nicholas Chiorazzi

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览13

暂无评分

摘要

Our data define the mechanism of action whereby dual inhibition of PI3K-δ,γ affects CLL B-cell numbers and T and myeloid cell pro-leukemia functions and support the use of duvelisib as a valuable approach for therapeutic interventions, including for patients refractory to BTKi.

查看译文

关键词

overcomes ibrutinib resistance,cll-supporting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要